RT Journal Article
SR Electronic
T1 Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 66
OP 74
DO 10.3899/jrheum.150382
VO 43
IS 1
A1 Pia Moinzadeh
A1 Gabriela Riemekasten
A1 Elise Siegert
A1 Gerhard Fierlbeck
A1 Joerg Henes
A1 Norbert Blank
A1 Inga Melchers
A1 Ulf Mueller-Ladner
A1 Marc Frerix
A1 Alexander Kreuter
A1 Christian Tigges
A1 Nina Lahner
A1 Laura Susok
A1 Claudia Guenther
A1 Gabriele Zeidler
A1 Christiane Pfeiffer
A1 Margitta Worm
A1 Sigrid Karrer
A1 Elisabeth Aberer
A1 Agnes Bretterklieber
A1 Ekkehard Genth
A1 Jan C. Simon
A1 Joerg H.W. Distler
A1 Ruediger Hein
A1 Matthias Schneider
A1 Cornelia S. Seitz
A1 Claudia Herink
A1 Kerstin Steinbrink
A1 Miklos Sárdy
A1 Rita Varga
A1 Hartwig Mensing
A1 Christian Mensing
A1 Percy Lehmann
A1 Gunther Neeck
A1 Christoph Fiehn
A1 Manfred Weber
A1 Matthias Goebeler
A1 Harald Burkhardt
A1 Michael Buslau
A1 Keihan Ahmadi-Simab
A1 Andrea Himsel
A1 Aaron Juche
A1 Ina Koetter
A1 Annegret Kuhn
A1 Michael Sticherling
A1 Martin Hellmich
A1 Kathrin Kuhr
A1 Thomas Krieg
A1 Jan Ehrchen
A1 Cord Sunderkoetter
A1 Nicolas Hunzelmann
A1 The German Network for Systemic Scleroderma
YR 2016
UL http://www.jrheum.org/content/43/1/66.abstract
AB Objective. Vasculopathy is a key factor in the pathophysiology of systemic sclerosis (SSc) and the main cause for Raynaud phenomenon (RP), digital ulcers (DU), and/or pulmonary arterial hypertension (PAH). It is so far unknown how patients with SSc are treated with vasoactive agents in daily practice. To determine to which extent patients with SSc were treated with different vasoactive agents, we used data from the German Network for Systemic Scleroderma registry.Methods. The data of 3248 patients with SSc were analyzed.Results. Patients were treated with vasoactive drugs in 61.1% of cases (1984/3248). Of these, 47.6% received calcium channel inhibitors, followed by 34.2% treated with angiotensin-converting enzyme (ACE) inhibitors, 21.1% treated with intravenous (IV) prostanoids, 10.1% with pentoxifylline, 8.8% with angiotensin 1 receptor antagonists (AT1RA), 8.7% with endothelin 1 receptor antagonists (ET1RA), 4.1% with phosphodiesterase type 5 (PDE5) inhibitors, and 5.3% with others. Patients with RP received vasoactive therapy in 63.3% of cases, with DU in 70.1%, and with PAH in 78.2% of cases. Logistic regression analysis revealed that patients with PAH were significantly more often treated with PDE5 inhibitors and ET1RA, and those with DU with ET1RA and IV prostanoids. In addition, 41.8% of patients were treated with ACE inhibitors and/or AT1RA. Patients registered after 2009 received significantly more often ET1RA, AT1RA, and IV prostanoids compared with patients registered prior to 2005.Conclusion. These data clearly indicate that many patients with SSc do not yet receive sufficient vasoactive therapy. Further, in recent years, a marked change of treatment regimens can be observed.